54results about How to "Extended dosing interval" patented technology

The invention relates to the field of Chinese medicine preparation, in particular to a method for preparing tripterine nano structure lipid carrier containing traditional Chinese medicine monomer and application of the tripterine nano structure lipid carrier in preparation of transdermal drugs used for treating psoriasis, rheumatoid arthritis, skin cancer and breast cancer. The tripterine nano structure lipid carrier is characterized by comprising the following components in parts by weight: 1 part of tripterine, 5-100 parts of mixed lipid, 0.5-10 parts of phospholipid, 0.1-15 parts of poloxamer-188 and 0.5-10 parts of vitamin E and tocopherol polyethylene glycol succinate, wherein the mixed lipid is composed of solid lipid monoglycerine and liquid lipid octylic acid / caprin according to the weight ratio of 1: 0.1-10: 1. Tripterine is prepared into the nano structure lipid carrier, the tripterine nano structure lipid carrier in a semi-solid or liquid preparation form is applied in a transdermal way, bioavailability of the tripterine can be improved, toxic response of tripterine can be reduced, and the nano structure lipid carrier provided by the invention has great clinical application value in the improvement of the treatment effect of tripterine.

The invention provides a paclobutrazol micro-capsule suspension preparation provided with sustained-release function, which includes the following components according to 100 parts by weight: 10 to 30 parts of film-forming materials, 5 to 40 parts of paclobutrazol, 5 to 10 parts of emulsifying agent and the rest parts of water. The potency of the suspension preparation is more moderate, the potency releases slower and lasts long, thus ensuring the adjustment of steady growth of plants and having the sustained-release function. The invention also provides a preparation method of the paclobutrazol micro-capsule suspension preparation.

The invention relates to a drug composition containing an antiviral peptide, application thereof in prevention or treatment of HIV (human immunodeficiency virus) infection and preparation of the corresponding drugs, and a method for preventing or treating HIV infection by using the drug composition.

The invention relates to a compound control-released percutaneous medicine plaster for treating high blood pressure and its preparation method, wherein the paste comprises laminated back lining layer, a pressure-sensitive adhesive framework form medicament-containing layer and a protective film, wherein the compound medicament comprises diuretics, central alpha-acceptor excitant and cirumferential alpha-receptor blocking agent, beta-receptor blocking agent, calcium antagonist and any two of the five categories of medicament for influencing angiotensin II formation and treating high blood pressure. The invention may realize medicine administration once in front of chest or behind the ears, wherein homeostasis blood concentration can be reached.

The invention relates to an erythropoietin analog with at least one extra glycosylation sites or a variant thereof. The invention also relates to a DNA sequence for coding the erythropoietin analog or the variant thereof, and a recombinant plasmid and a host cell for expressing the analog or the variant thereof.

A compound powder injection or freeze-dried powder injection is prepared from the sodium (or potassium) salt of probenecid and the beta-lactam kind of antibiotics including penicillin G, ampicillin, ancef, cefuroxime, cefotaxime and cefoxitin. It can elongate the half life of antibiotic, increase the AUC and plasma level and prevent the generation of drug-resistant bacteria.

The invention provides an anti-human CTGF antibody having a superior binding activity and / or a superior neutralization activity compared with those of conventional anti-human CTGF antibodies; and a means for preventing or treating various diseases in which human CTGF is involved in the formation of clinical conditions thereof, including renal diseases such as chronic kidney disease and diabetic nephropathy, using the above-mentioned anti-human CTGF antibody. An anti-human CTGF antibody containing a heavy-chain variable region comprising the amino acid sequence represented by SEQ ID NO: 10 and a light-chain variable region comprising the amino acid sequence represented by SEQ ID NO: 4.

The invention discloses a PEG-PLGA sustained release microsphere with encapsulated buprenorphine and a preparation method thereof. The preparation method is as below: conducting debydrochlorination on buprenorphine to prepare alkali, and conducting a single emulsion method to obtain the PEG-PLGA sustained release microsphere with encapsulated buprenorphine. The weight ratio of buprenorphine (calculated by buprenorphine hydrochloride) to polyethylene glycol-polylactic acid-glycolic acid copolymer is 2-6:10, and the buprenorphine sustained release microsphere has particle size of 10-50 micron. The invention employs for the first time the hydrochloric acid-single emulsion method to prepare the buprenorphine sustained release microspheres with high drug loading, obvious sustained-release effect and good biocompatibility, and can develop a variety of administration approaches, such as intravenous injection, and subcutaneous and intramuscular non-intravenous administration approaches. The invention has good application prospect, and can improve patient compliance.

The gatifloxacin ear drop is prepared with gatifloxacin or its salt as the main component and the supplementary materials including glycerin, ethanol and sterilized water for injection, pure water or distilled water. The present invention also discloses the preparation process of the gatifloxacin ear drop. As one fourth generation oxyquinolone type antibacterial medicine, the gatifloxacin ear drop has high bioavailability, reduced medicine taking times, less systemic untoward reaction, high patient's compliance and less drug resistance.

Provided are an anti-human NGF antibody which is reduced in the influence on fetuses and the risk of adverse side effects including thrombosis while keeping a high neutralizing activity, and which has excellent safety, or an antigen-binding fragment thereof; and a means, utilizing the antibody or an antigen-binding fragment thereof , for preventing or treating various diseases for which human NGF is involved in the development of a disease state. An Fab' fragment of an anti-human NGF antibody comprises a heavy-chain variable region comprising the amino acid sequence represented by SEQ ID NO: 6 and a light-chain variable region comprising the amino acid sequence represented by SEQ ID NO: 4.

The invention discloses a preparation method of environmentally-friendly pyrethrin controlled-release microspheres. The method comprises the following steps: (1) performing ultrasonic cleaning on magnetic nanoparticles, and adding ethanol to prepare a magnetic nanoparticle solution; (2) dissolving half of the magnetic nanoparticle solution, a pyrethrin original drug and an environmentally-friendlyhigh-molecular polymer into an oil phase; (3) dissolving the other half of the magnetic nanoparticle solution and an emulsifying agent into a water phase; (4) performing magnetization on the oil phase and the water phase to make the oil phase and the water phase have opposite magnetism; (5) extruding the magnetized oil phase and water phase at a synchronous speed into a supercritical CO2 solvent;(6) adding an antifoaming agent dropwise, and performing a reaction for 12-14 h; (7) performing reduced-pressure drying to obtain controlled-release pyrethrin microspheres; and (8) preparing the pyrethrin sustained-release microsphere wettable powder. According to the preparation method provided by the invention, the pyrethrin controlled-release microspheres prepared by the method have uniform particles and a long lasting period, can reduce frequency of pesticide application and a total amount of the pesticide application, prolong a pesticide application interval, and improve a utilization rate of a pesticide.

The invention relates to an erythropoietin analogue containing at least one extra glycosylation site or a variant of the erythropoietin analogue. The invention also relates to a DNA (Deoxyribonucleic Acid) sequence for encoding the erythropoietin analogue or the variant thereof as well as a recombinant plasmid and a host cell which are supplied for the analogue or the variant thereof to express.

The invention relates to a hemopoietin analogue with at least one additional glycosylation site or a variant thereof. The invention further relates to a DNA (deoxyribonucleic acid) sequence for coding the hemopoietin analogue or the variant thereof as well as a recombinant plasmid and a host cell for expression of the hemopoietin analogue or the variant thereof.

The invention discloses an anti-infection wound-repairing pharmaceutical composition in the technical field of biomedicines. The anti-infection wound-repairing pharmaceutical composition is prepared from the following raw materials in parts by weight, 30-40 parts of chitosan hydrochloride, 80-120 parts of cunninghamia lanceolata, 30-36 parts of bletilla striata, 2-8 parts of borneol and 450-550 parts of glycerol. The pharmaceutical composition is applied to prepare a film spraying preparation, and the preparation method comprises the following steps, step 1, weighing the raw materials in proportion, processing cunninghamia lanceolata and bletilla striata, and grinding the processed cunninghamia lanceolata and bletilla striata into fine powder; step 2, adding PVA1788 and chitosan hydrochloride to distilled water under water bath condition at 40 DEG C, and conducting magnetic stirring to be completely dissolved; step 3, adding cunninghamia lanceolata powder, bletilla striata powder and borneol, then adding glycerol, continuously conducting magnetic stirring to be completely dissolved, and standing at room temperature until foams are eliminated; step 4, adding absolute ethyl alcohol,conducting uniform stirring, standing for 5 minutes, and conducting bottling; and step 5, conducting sub-packaging and ultraviolet sterilization. The pharmaceutical composition disclosed by the invention has the effects of effusion resistance, adhesion prevention, hemostasis, anti-infection, promotion of wound healing, etc.

The invention relates to desvenlafaxine succinate sustained-release tablets. The desvenlafaxine succinate sustained-release tablets are prepared from the raw materials in parts by weight: 50 parts of desvenlafaxine succinate, 150-240 parts of sustained-release framework material and 10-100 parts of lubricant. A preparation method of the desvenlafaxine succinate sustained-release tablets comprises the steps of preparing materials, mixing, granulating, mixing, tabletting and carrying out aluminum-plastic packaging. The desvenlafaxine succinate sustained-release tablets disclosed by the invention can be used for effectively curing major depression and are high in effect taking speed, low in side effect, stable in drug release and good in controllability; compared with the tablets currently on the market, the technical advantages are obvious, the bioavailability is improved, novel sustained-release preparations are adopted, and sustained release means delaying the drug release rate of a drug from a dosage form, lowering the organism entering absorption rate of the drug and thus exerting a more stable treatment effect.

The invention discloses a burst release-free irinotecan microsphere and a preparation method thereof. The irinotecan microsphere comprises irinotecan and a polylactic acid-glycolic acid copolymer (poly(lactic-co-glycolicacid), PLGA), wherein the weight ratio of the irinotecan to the PLGA is 1 to (10-40), and the grain size of the irinotecan microsphere is 1-5 micrometers. A long-acting burst release-free irinotecan microsphere can be prepared from the irinotecan and the PLGA at a specific ratio, and the slow release period of the irinotecan microsphere is longer than 40 days, so the medication frequency is obviously reduced, a peak and valley phenomenon of the medicine is reduced, the bioavailability of the irinotecan is improved and toxic and side effects of the medicine are reduced.

The invention relates to a pesticide used for preventing and controlling leaf miners, which is prepared by mixing trichlorphon, pesticide adjuvant and water, wherein the proportion of the trichlorphon (mass), the pesticide adjuvant (volume) and the water (volume) is 1:1:200; and the pesticide adjuvant is of the 75ml of mixture prepared by mixing water and the following raw materials: 14-30g of sodium dodecyl benzene sulfonate, 70-150g of edible white sugar and 14-30g of bone glue. The pesticide has the benefits of improving the pesticide absorption of crops and improving the pesticide toxicity for the larvas of the leaf miners.

The invention discloses an eye drop which mainly contains amikacin or amikacin salt and chitosan or the derivative of chitosan. The eye drop comes into being through the dissolving of a medicine compound into the injection water which is then added with leakage pressure adjusting agent, pH value adjusting agent, acid-bases buffer, chemical inhibitor and bacteriostatic agent, then the addition of the full dose of injection water after the dissolving, then the filtering and sterilization of the solution, with the finished product obtained finally after the canning and sealing. The invention, on one hand, reduces the dosage of amikacin through the coordinate antibacterial action of chitosan, the derivative of chitosan and the amikacin, thus reducing the toxic and side effect and particularly reducing the toxicity to ears and kidneys. On the other hand, the invention prolongs the time for which the medicine stays in the eyes through taking advantage of the solution with a certain viscosity obtained after the dissolving of chitosan and the derivative of chitosan into the water, thus improving the use efficiency of the medicine, reducing the medicine using times and prolonging the intervals for medicine using. The invention has a good result in curing the eye infection caused by sensitive bacteria, such as conjunctivitis, keratitis, sclerotitis, etc.

The invention discloses a gatifloxacin ophthalmic gel and a preparation method thereof, aiming at overcoming the defects of drug resistance caused by long-term use of the existing ear drops and many times of medication by patients, and providing a gatifloxacin ophthalmic gel eye gel. It is a medicine containing the following percentages by weight: 0.05%-0.4% of gatifloxacin, 0.5%-1.5% of carbomer, and 1%-2% of triethanolamine. The preparation steps are as follows: sprinkle carbomer on the surface of glycerin, grind and infiltrate, then grind with distilled water to make it fully swell; dissolve triethanolamine in distilled water, add supernatant and grind to make gel matrix (III); Add gatifloxacin to distilled water, stir to dissolve; then add propylene glycol and stir well to make a mixed solution (IV); slowly add the mixed solution (IV) to (III), add distilled water to the entire amount, and grind until uniform.

The application of the invention relates to an application of a compound of a formula I or pharmaceutically acceptable salt, ester, solvate, prodrug, active metabolite, crystal, stereoisomer, tautomeror geometric isomer thereof, or a medical composition comprising the compound of the formula I or the pharmaceutically acceptable salt, the ester, the solvate, the prodrug, the active metabolite, thecrystal, the stereoisomer, the tautomer or the geometrical isomer to preparation of drugs for preventing or treating tyrosine kinase related diseases.

The invention discloses an indole compound for preparing a coronavirus therapeutic drug, and belongs to the field of chemical medicines. The indole compound shown in the general formula (I) or the pharmaceutically acceptable salt thereof has excellent tubulin polymerization inhibition activity, and can inhibit tubulin and destroy cytoskeleton, so that coronavirus cannot be transported, and the purpose of effectively treating virus infection is achieved. Meanwhile, the compound disclosed by the invention is relatively good in metabolic stability and relatively long in metabolic half-life period, so that the medical dosage can be reduced, and the administration time interval can be expanded.

The invention relates to the technical field of medicine preparations, in particular to a Mongolian medicine paste for child hyperpyrexia and a preparation method and application method thereof. Mongolian medicine eridun-7 soup is used as a powdery preparation for solving the problems that treatment is influenced due to poor adaptability and difficult application during child hyperpyrexia treatment. The oral powdery preparation is changed into an external use paste, extracts of all medicinal materials are used for replacing raw material medicine, and the treatment effect after use is better. The Mongolian medicine paste for child hyperpyrexia has the advantages that 1, the first-pass effect of the liver and degradation of the medicine in the gastrointestinal tract can be avoided, medicineabsorption is not influenced by gastrointestinal factors, and the individual difference of medicine application is reduced; 2, the medicine can enter the human body at the constant speed for a long time after one-time medicine application, the frequency of medicine application is reduced, and the interval of medicine application is prolonged; 3, the medicine application area is changed, the medicine application dosage is adjusted, and a patient takes the medicine by himself / herself; 4, the Mongolian medicine paste has the sustained or controlled release effect, the medicine can be slowly released at a certain speed, the constant plasma concentration is formed in the skin accordingly, and convenience is provided for prolonging the treatment time of the medicine.

The invention discloses a norethisterone acetate-containing compound estradiol transdermal sustained release preparation and a preparation method thereof. The preparation comprises a backing layer, a protective film and a frame layer between the backing layer and the protective film, wherein the frame layer comprises an upper frame layer, a lower frame layer and a controlled release film between the upper frame layer and the lower frame layer; and the backing layer covers the surface of the lower frame layer. The upper and lower frame layers are respectively wrapped by estradiol and norethisterone acetate in a certain ratio, an intermediate frame layer is wrapped by a special transdermal patch of the controlled release film, estrogen estradiol effects in relieving or eliminating climacteric syndromes and preventing osteoporosis are fully played, and the preparation also has the characteristics of small stimulus to human bodies, small side effects, quality stability and long effective time.

The invention discloses a nitric oxide releasing ointment, a preparation method and application thereof. The method comprises the following steps: (1) dissolving polyethyleneimine in an organic solvent, adding sodium methoxide, mixing uniformly, carrying out NO loading reaction, and obtaining polyethyleneimine NO donor material; (2) dissolving polyethyleneimine NO donor material The body material is dissolved in polyvinyl alcohol aqueous solution to obtain polyethyleneimine NO donor material solution; (3) liquid paraffin, glyceryl monostearate, white vaseline and lanolin are mixed uniformly to obtain an oil phase; glycerin, Add Span 80 and Tween 80 into water and mix evenly to obtain a water phase; add the water phase to the oil phase to obtain a mixed solution; (4) add polyethyleneimine NO donor material solution to the mixed solution to obtain a released Nitric oxide ointment. The prepared ointment has good antibacterial and slow release effects on various bacteria, and is of great significance for the treatment of various microbial diseases and the improvement of people's health.